Common Seizure Drug May Prevent Alzheimer's Years Early

Scientists just found that a widely available seizure medication could prevent Alzheimer's disease if taken early enough. The discovery offers new hope for millions at risk of developing dementia.

Levetiracetam, sold as Keppra since 1999, does something remarkable beyond controlling seizures. Northwestern University researchers discovered it stops the formation of amyloid beta 42, the toxic protein fragments that clump together in Alzheimer's patients' brains.

The team tested the drug in animal models, cultured human neurons, and even brain tissue from people with Down syndrome who face high Alzheimer's risk. In every case, the medication prevented those harmful proteins from forming.

"While many Alzheimer's drugs currently clear existing plaques, we've identified a mechanism that prevents production of these peptides in the first place," said Jeffrey Savas, the study's lead researcher and associate professor at Northwestern University Feinberg School of Medicine.

Here's the catch: patients would need to start taking it very early, possibly 20 years before any symptoms appear. Our brains naturally avoid creating these toxic proteins when we're young, but that protective ability weakens with age.

The researchers analyzed previous clinical data and found encouraging results. Alzheimer's patients already taking levetiracetam for seizures showed significantly slower cognitive decline and lived longer than those not on the medication.

Why This Inspires

This research flips the script on Alzheimer's treatment. Instead of waiting until the brain has already suffered damage, we might soon catch the disease before it starts.

The medication is already FDA-approved, affordable, and available in pharmacies right now. While it's not perfect and breaks down quickly in the body, researchers are working on an improved version that lasts longer and targets the brain more effectively.

Even more promising: the team plans to test the drug in people with genetic forms of Alzheimer's, who know decades in advance they'll likely develop the disease. These individuals could be the first to benefit from true prevention rather than just symptom management.

The findings appeared in Science Translational Medicine and represent years of work funded by the National Institutes of Health and Cure Alzheimer's Fund. While human trials are still needed, this discovery opens a door that's been closed for too long.

Prevention beats treatment every time, and for the 6.7 million Americans living with Alzheimer's, this research lights a path forward.